- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Tourmaline Bio, Inc.: Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 | 3 | GlobeNewswire (USA) | ||
| 07.11. | Tourmaline Bio files for $350M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.11. | Tourmaline Bio, Inc.: Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 79 | GlobeNewswire (Europe) | - On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 - - Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry... ► Artikel lesen | |
| 07.11. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Tourmaline Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Tourmaline Bio shares get buy rating on IL-6 study optimism | 6 | Investing.com | ||
| TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
| 15.10. | Tourmaline Bio, Inc.: Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 | 3 | GlobeNewswire (USA) | ||
| 11.10. | Tourmaline Bio stock slides 7% amid news of CMO's departure | 1 | Seeking Alpha | ||
| 11.10. | Guggenheim reiterates Buy on Tourmaline Bio shares, keeps price target | 2 | Investing.com | ||
| 11.10. | Tourmaline Bio to present research at Cardiometabolic Congress | 2 | Investing.com | ||
| 11.10. | Tourmaline Bio, Inc.: Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress | 1 | GlobeNewswire (USA) | ||
| 10.10. | Tourmaline Bio announces CMO resignation | 2 | Investing.com | ||
| 10.10. | Tourmaline Bio gibt Rücktritt des Chief Medical Officer bekannt | 1 | Investing.com Deutsch | ||
| 10.10. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.10. | Tourmaline Bio gründet Beirat für Herzmedikament | 2 | Investing.com Deutsch | ||
| 08.10. | Tourmaline Bio forms advisory board for heart drug | 1 | Investing.com | ||
| 08.10. | Tourmaline Bio, Inc.: Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
| 11.09. | Tourmaline Bio shares poised for growth with promising cardiovascular study results | 1 | Investing.com | ||
| 11.09. | Tourmaline Bio-Aktien vor vielversprechendem Wachstum dank positiver kardiovaskulärer Studienergebnisse | 1 | Investing.com Deutsch | ||
| 05.09. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,00 | +0,36 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | Evotec Aktie: Alarm! Probleme bahnen sich an | ||
| CUREVAC | 2,732 | -1,37 % | CureVac Aktie: Zukunftsprojekte auf gutem Weg! | Die CureVac N.V. verzeichnete in den letzten Handelstagen eine positive Entwicklung an der Börse. Der Tübinger mRNA-Spezialist konnte Ende November einen Kursanstieg von 2,1 Prozent erreichen und notierte... ► Artikel lesen | |
| NOVAVAX | 8,344 | -0,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| INFLARX | 2,232 | -3,12 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
| CSL | 174,10 | +2,00 % | CSL LIMITED: Application for quotation of securities - CSL | ||
| OCULAR THERAPEUTIX | 9,582 | +3,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1 | ||
| COHERUS | 1,822 | +40,06 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| CHIMERIX | 0,817 | -3,08 % | Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,190 | +15,09 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 19,500 | -4,41 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,090 | +1,68 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 17,500 | -2,78 % | Cidara Therapeutics, Inc. - 8-K, Current Report | ||
| PIERIS PHARMACEUTICALS | 15,400 | 0,00 % | PIERIS PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| NEXTCURE | 1,118 | +0,72 % | NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results | Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md.... ► Artikel lesen |
Das Unternehmen TOURMALINE BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,400 Euro und damit -1,28 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TOURMALINE BIO INC finden Sie auf Wallstreet Online.
